ACT-CHIK Kicks Off in Kigali

By Kelly Prifti, Project Manager

In June, the members of the “ACT-CHIK” consortium gathered in Kigali, Rwanda to kick-off a new EDCTP3-funded project.  

Entitled Accelerating Clinical Trials for CHIKungunya Vaccine in Africa, ACT-CHIK is coordinated by Institut Pasteur, under the scientific leadership of University of Rwanda and in collaboration with Institut Pasteur de Dakar (IPD, Senegal), Fiocruz (Brazil), IRRUA Specialist Teaching Hospital (Nigeria), Kenya Medical Research Institute (Kenya) and International Vaccine Institute (South Korea).  

With €15.3 million in EU funding, ACT-CHIK will advance the clinical development of MV-CHIK — a measles-virus-based chikungunya vaccine originally developed at Institut Pasteur — through a large-scale Phase Ib/III clinical trial in four African countries, while preparing for technology transfer to an African vaccine manufacturer (IPD) and paving the way for licensure of the vaccine in Africa. 

Learn more about ACT-CHIK